AIDS Drug Combos Still Moving Slowly After FDA Guidance
Executive Summary
GlaxoSmithKline and Boehringer Ingelheim are in discussions with FDA on a Combivir/Viramune co-package submission after signing a "letter of intent" to develop the product
You may also be interested in...
Co-Packaged HIV Drug User Fees Likely To Be Waived By AIDS Relief Plan
Most fixed-dose combination and co-packaged versions of previously approved antiretroviral HIV therapies are unlikely to require user fees under the President's $15 bil. Emergency Plan for AIDS Relief, according to a 1draft guidance released April 15
Co-Packaged HIV Drug User Fees Likely To Be Waived By AIDS Relief Plan
Most fixed-dose combination and co-packaged versions of previously approved antiretroviral HIV therapies are unlikely to require user fees under the President's $15 bil. Emergency Plan for AIDS Relief, according to a 1draft guidance released April 15
FDA Drug Development Strategy Includes Initiating Meetings With Firms
FDA will seek legislation empowering the agency to initiate meetings with industry on drug development, Acting Commissioner Lester Crawford, PhD, said